Evidence map›Paper›PMID 34392312›Full record

SynthesisSpinal cord2021

Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury.

Faheem I Bhatti, Oliver D Mowforth, Max B Butler, Aniqah I Bhatti, Sylva Adeeko, Melika Akhbari, Rory Dilworth, Ben Grodzinski, Temidayo Osunronbi, Luke Ottewell and 10 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Spinal cord, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Transcriptomic Profiling after In Vitro ΔPharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Review
  7. Article
  8. Lentiviral-Induced Spinal Cord Gliomas in Rat Model.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Faheem I BhattiDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-3897-4196
Oliver D MowforthDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Max B ButlerDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2536-0534
Aniqah I BhattiDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Sylva AdeekoMyelopathy.org, Cambridge, UK.
Melika AkhbariMyelopathy.org, Cambridge, UK.
Rory DilworthMyelopathy.org, Cambridge, UK.
Ben GrodzinskiDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-8839-4718
Temidayo OsunronbiMyelopathy.org, Cambridge, UK.
Luke OttewellMyelopathy.org, Cambridge, UK.
Jye Quan TehDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-0286-2953
Sophie RobinsonMyelopathy.org, Cambridge, UK.
Gayathri SureshMyelopathy.org, Cambridge, UK.
Unaiza WaheedMyelopathy.org, Cambridge, UK.
Benn WalkerMyelopathy.org, Cambridge, UK.
Isla KuhnCambridge University Medical Library, Cambridge, UK.ORCID http://orcid.org/0000-0002-2879-4020
Lara SmithMyelopathy.org, Cambridge, UK.
Richard D BartlettDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2019-8125
Benjamin M DaviesDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. Benjamin.davies4@nhs.net.
Mark R N KotterDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5145-7199

Funding

DH | National Institute for Health Research (NIHR) CS-2015-15-023
6 · The paper itself

Abstract

STUDY

designSystematic review.

objectivesTo evaluate the impact of cannabinoids on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic spinal cord injury (SCI), with the aim of determining suitability for clinical trials involving SCI patients.

methodsA systematic search was performed in MEDLINE and Embase databases, following registration with PROPSERO (CRD42019149671). Studies evaluating the impact of cannabinoids (agonists or antagonists) on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic SCI were included. Data extracted from relevant studies, included sample characteristics, injury model, neurobehavioural outcomes assessed and study results. PRISMA guidelines were followed and the SYRCLE checklist was used to assess risk of bias.

resultsThe search returned 8714 studies, 19 of which met our inclusion criteria. Sample sizes ranged from 23 to 390 animals. WIN 55,212-2 (n = 6) and AM 630 (n = 8) were the most used cannabinoid receptor agonist and antagonist respectively. Acute SCI models included traumatic injury (n = 16), ischaemia/reperfusion injury (n = 2), spinal cord cryoinjury (n = 1) and spinal cord ischaemia (n = 1). Assessment tools used assessed locomotor function, pain and anxiety. Cannabinoid receptor agonists resulted in statistically significant improvement in locomotor function in 9 out of 10 studies and pain outcomes in 6 out of 6 studies.

conclusionModulation of the endo-cannabinoid system has demonstrated significant improvement in both pain and locomotor function in pre-clinical SCI models; however, the risk of bias is unclear in all studies. These results may help to contextualise future translational clinical trials investigating whether cannabinoids can improve pain and locomotor function in SCI patients.

Indexed as

CannabinoidsSpinal Cord InjuriesAnimalsBiasHumansPainCannabinoids

Identifiers

PMID34392312
PMCPMC8629762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.